CBI Announces 3rd Summit on Animal Health Marketing Strategies - Co-Located with CVC Kansas City

WOBURN, Mass., June 30, 2011 /PRNewswire/ -- Advanstar|CBI recently announced the full agenda for their 3rd Summit on Animal Health Marketing Strategies - Co-Located with CVC Kansas City. The Summit takes place on August 29, 2011 in Kansas City, MO.

Animal Health Marketing Strategies' speaker faculty includes leading experts from Boehringer-Ingelheim Vetmedica, Inc. (BIVI), Pfizer Animal Health, Novartis Animal Health and many more.  

Attendees have the opportunity to participate in an Executive Roundtable: Animal Health Marketing Trends Analysis - Where are We Headed? Here, animal health marketing professionals discuss the trends in the industry and offer insight into where the industry is headed in the next 5-10 years.

This Summit is the industry's only opportunity for animal health and marketing professionals to discuss consumer spending and purchasing behavior, product innovation, sales force consolidation, social media and more. For more information on the conference or to view the entire agenda, please visit http://www.cbinet.com/animalhealth.  

About CBI:

CBI, a subsidiary of Advanstar, is the leading provider of market-driven, unbiased conferences for the pharmaceutical, biotechnology, medical device and healthcare industries. CBI offers specialized information presented in interactive formats by thought leaders and regulators. CBI's conferences provide a unique platform for concrete, real-life examples that can be applied to any organization immediately, significantly impacting both costs and revenue. For more information, please visit http://www.cbinet.com.

For additional information or media inquiries, please contact Kristina Weljkovic, Marketing Manager, at 339-298-2285.

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.

SOURCE CBI

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.